Page 1 sur 1

Qualité de vie 30 mois après traitement

Posté : 10 févr. 2011 16:25
par Marsu
http://www.ncbi.nlm.nih.gov/pubmed/21303350
Acta Neurol Scand. 2011 Feb 9. doi: 10.1111/j.1600-0404.2010.01482.x. [Epub ahead of print]
European neuroborreliosis: quality of life 30 months after treatment.
Eikeland R, Mygland A, Herlofson K, Ljøstad U.

Department of Neurology, Sørlandet Hospital, Arendal, Norway Department of Neurology, Sørlandet Hospital, Kristiansand, Norway Department of Clinical Medicine, University of Bergen, Bergen, Norway Clinic of Rehabilitation, Sørlandet Hospital, Kristiansand, Norway.
Abstract
Eikeland R, Mygland Å, Herlofson K, Ljøstad U. European neuroborreliosis: quality of life 30 months after treatment. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2010.01482.x. © 2011 John Wiley & Sons A/S. Objectives -  The prognosis after Lyme neuroborreliosis (LNB) is debated. The aim of this study was to assess health-related Quality of Life (QoL) and neurological symptoms 30 months after treatment in European patients with LNB. Materials and methods -  In a prospective case-control designed study, we investigated 50 well-characterized patients with LNB who had participated in a treatment trial for LNB 30 months earlier and 50 matched control persons with the health QoL questionnaire Short-Form 36 (SF-36), the Fatigue Severity Scale (FSS), the Montgomery and Åsberg Depression Rating Scale (MADRS), the Starkstein Apathy Scale (SAS), and the Mini Mental State (MMS). Clinical and demographic data were collected by semi-structured interviews and clinical neurological examination. Results -  Lyme neuroborreliosis-treated patients scored lower than control persons in the SF-36 domains physical component summary (PCS) (44 vs 51 P < 0.001) and mental component summary (MCS) (49 vs 54 P = 0.010). They also scored lower than control persons in all the SF-36 subscales, except for bodily pain, and on FSS (3.5 vs 2.1 P < 0.001), but not on MMS (28 vs 29 P = 0.106). There was a difference in MADRS (3.1 vs 0. 8 P = 0.003) and SAS (13 vs 11 P = 0.016), but the scores were low in both groups. Fatigue was the most frequently reported symptom among LNB-treated patients (50%). Patients who reported complete recovery (56%) after LNB had similar QoL scores as the controls. Conclusion -  European persons treated for LNB have poorer health-related QoL and have more fatigue than persons without LNB.

© 2011 John Wiley & Sons A/S.
PMID: 21303350 [PubMed - as supplied by publisher]

Re: Qualité de vie après 30 mois de traitement

Posté : 10 févr. 2011 17:40
par casada
Merci Marsu
:lo
Alors , gardons le moral tout de même!! et investissons dans les anti-fatigue..Si j'ai bien compris! Car mon anglais date un peu beaucoup. :wink: